MCID: CHR189
MIFTS: 12

Chromosome 12p Deletion

Categories: Rare diseases

Aliases & Classifications for Chromosome 12p Deletion

MalaCards integrated aliases for Chromosome 12p Deletion:

Name: Chromosome 12p Deletion 53 29
Loss of Chromosome 12p 73
Partial Monosomy 12p 53
12p Deletion 53
12p Monosomy 53
Deletion 12p 53
Monosomy 12p 53

Classifications:



External Ids:

UMLS 73 C1517955

Summaries for Chromosome 12p Deletion

MalaCards based summary : Chromosome 12p Deletion, also known as loss of chromosome 12p, is related to distal monosomy 12p and lymphocytic leukemia. The drugs Sodium oxybate and Oxazepam have been mentioned in the context of this disorder.

Related Diseases for Chromosome 12p Deletion

Diseases related to Chromosome 12p Deletion via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 distal monosomy 12p 11.2
2 lymphocytic leukemia 10.1
3 chromosomal triplication 10.0
4 chromosome 11q duplication 10.0
5 germ cells tumors 10.0
6 myeloma, multiple 10.0
7 leukemia, acute lymphoblastic 10.0
8 acute lymphoblastic leukemia, childhood 10.0
9 acute lymphocytic leukemia 10.0
10 microcephaly 9.9
11 dandy-walker complex 9.9

Graphical network of the top 20 diseases related to Chromosome 12p Deletion:



Diseases related to Chromosome 12p Deletion

Symptoms & Phenotypes for Chromosome 12p Deletion

Drugs & Therapeutics for Chromosome 12p Deletion

Drugs for Chromosome 12p Deletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 4 502-85-2 5360545
2
Oxazepam Approved Phase 4 604-75-1 4616
3
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
4
Povidone Approved Phase 4 9003-39-8
5
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
6 Anesthetics, General Phase 4
7 GABA Agents Phase 4
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Anti-Anxiety Agents Phase 4
10 GABA Modulators Phase 4
11 Central Nervous System Depressants Phase 4
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anesthetics, Intravenous Phase 4
14 Anti-Infective Agents, Local Phase 4
15 Anesthetics Phase 4
16 Tranquilizing Agents Phase 4
17 Psychotropic Drugs Phase 4,Not Applicable
18 Adjuvants, Anesthesia Phase 4
19 Hypnotics and Sedatives Phase 4
20 Vaccines Phase 4,Phase 1,Phase 2
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Vitamin D2 Phase 4
23 Trace Elements Phase 4,Not Applicable
24 Calciferol Phase 4,Not Applicable
25 Vitamins Phase 4,Not Applicable
26 Bone Density Conservation Agents Phase 4
27 Micronutrients Phase 4,Not Applicable
28 Ergocalciferols Phase 4
29
Idarubicin Approved Phase 3 58957-92-9 42890
30
Etoposide Approved Phase 3,Phase 2,Not Applicable 33419-42-0 36462
31
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
32 tannic acid Approved Phase 3
33
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
34
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 46835353 6436030 5284616
36
Everolimus Approved Phase 3 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
38
Pancrelipase Approved, Investigational Phase 3,Phase 2 53608-75-6
39 Antibiotics, Antitubercular Phase 3,Phase 2,Not Applicable
40 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
42 Topoisomerase Inhibitors Phase 3,Phase 2,Not Applicable
43 Etoposide phosphate Phase 3,Phase 2,Not Applicable
44 Adrenergic Agonists Phase 3
45 Respiratory System Agents Phase 3,Not Applicable
46 Adrenergic beta-Agonists Phase 3
47 Formoterol Fumarate Phase 3
48
Salmeterol xinafoate Phase 3 94749-08-3 56801
49 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
50 Bronchodilator Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
2 Bioequivalence of Ethylenediamine Dihydrochloride Study Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
3 The Safety and Immune Response to Influenza Vaccination in Pregnant Women Completed NCT01514708 Phase 4
4 Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients Completed NCT00294866 Phase 4 Paricalcitol
5 Metformin and Systemic Inflammation in HIV Not yet recruiting NCT03774108 Phase 4 Metformin Hydrochloride 850 MG
6 Effect of Aerobic Training in Moderate or Severe Asthmatic Patients Unknown status NCT02033122 Phase 3
7 Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result Completed NCT00146120 Phase 3 Idarubicin;Cytosin-Arabinosid;Etoposide;All-trans Retinoid acid
8 Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD Completed NCT00064402 Phase 3 arformoterol tartrate inhalation solution;arformoterol tartrate inhalation solution;arformoterol tartrate inhalation solution;Salmeterol;Placebo
9 A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. Completed NCT02040584 Phase 3 Minimisation of TAC;TAC + MMF + corticosteroids
10 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Recruiting NCT02514928 Phase 3
11 Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response Terminated NCT00159926 Phase 3
12 A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease Completed NCT00265122 Phase 2 Ustekinumab 90 mg;Ustekinumab 4.5 mg/kg;Placebo SC;Placebo IV
13 A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis Completed NCT00207727 Phase 2 CNTO 1275
14 Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer Completed NCT00064298 Phase 2
15 Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia Completed NCT02062190 Phase 2 resveratrol
16 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2 Rituximab
17 Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA) Completed NCT00403273 Phase 2 Botulinum toxin A;Normal Saline
18 A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis Completed NCT00976599 Phase 2 CP-690,550 + methotrexate;Placebo + Methotrexate
19 A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection Completed NCT02391805 Phase 2 Entecavir;Placebo;RO6864018;Tenofovir
20 University of Wisconsin Meditation & Exercise Cold Study Completed NCT01654289 Phase 2
21 A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Completed NCT01135511 Phase 2 CP-690,550 Eye drops;CP-690,550 Eye drops;CP-690,550 Eye drops;CP-690,550 Eye drops-vehicle;Sodium Hyaluronate
22 Probiotics and Gut Health Recruiting NCT03418857 Phase 1, Phase 2 Yogurt smoothie with BB-12;Yogurt smoothie
23 Effects of Metformin in a Non-Diabetic Patient Population Recruiting NCT03772964 Phase 1, Phase 2 MetFORMIN Hydrochloride ER
24 Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning Recruiting NCT02952716 Phase 1, Phase 2
25 Therapeutic Vaccination in Treated HIV Disease Recruiting NCT03606213 Phase 1, Phase 2
26 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Recruiting NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
27 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Recruiting NCT03058289 Phase 1, Phase 2 INT230-6
28 Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease Active, not recruiting NCT02611167 Phase 1, Phase 2
29 Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer Terminated NCT01116791 Phase 2
30 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
31 Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects Completed NCT02211170 Phase 1 BIBR 796 BS, low dose;BIBR 796 BS, high dose;Placebo;Lipopolysaccharide
32 A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects Completed NCT02798978 Phase 1 GSK1795091;Placebo
33 PK/PD of EA-230 During Endotoxemia Completed NCT02629874 Phase 1 EA-230;Endotoxin;Placebo
34 Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma Completed NCT01974661 Phase 1
35 Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants Recruiting NCT03530917 Phase 1 RO7020531
36 A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531 Recruiting NCT02956850 Phase 1 RO7020531
37 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Active, not recruiting NCT01703507 Phase 1 Ipilimumab
38 Xanthohumol Metabolism and Signature Not yet recruiting NCT03735420 Phase 1 Xanthohumol;Placebo oral capsule
39 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment Not yet recruiting NCT03780972 Phase 1 ONL1204
40 Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma Terminated NCT02243189 Phase 1 JNJ-43260295;Placebo;Nasal Allergen Challenge
41 Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies Unknown status NCT00837278
42 Genetic Disease Gene Identification Unknown status NCT00916903
43 Identification of Biomarkers in the Legal Medical Skin Wounds Unknown status NCT02898636
44 Exercise-induced Bronchoconstriction in School Children Unknown status NCT01798823
45 Cytokine and Body Composition's Changes in Overweight/Obese Women Unknown status NCT02766426 Not Applicable
46 Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma Completed NCT00323206 Not Applicable
47 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma Completed NCT02097134 Not Applicable Melphalan
48 Polymorphism C677T MTHFR and Folate Intake in Inflammatory Biomarkers Completed NCT03186196 Not Applicable
49 Keratinocyte Growth Factor and Cytokines in Burns. Completed NCT01302223
50 Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder Completed NCT01862653 Not Applicable

Search NIH Clinical Center for Chromosome 12p Deletion

Genetic Tests for Chromosome 12p Deletion

Genetic tests related to Chromosome 12p Deletion:

# Genetic test Affiliating Genes
1 Chromosome 12p Deletion 29

Anatomical Context for Chromosome 12p Deletion

Publications for Chromosome 12p Deletion

Articles related to Chromosome 12p Deletion:

# Title Authors Year
1
Chromosome 12p Deletion Spanning the GRIN2B Gene Presenting With a Neurodevelopmental Phenotype: A Case Report and Review of Literature. ( 28503605 )
2016
2
Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. ( 25831238 )
2015
3
Analysis of chromosome 12p deletion in plasma cell dyscrasias. ( 21982640 )
2012

Variations for Chromosome 12p Deletion

Expression for Chromosome 12p Deletion

Search GEO for disease gene expression data for Chromosome 12p Deletion.

Pathways for Chromosome 12p Deletion

GO Terms for Chromosome 12p Deletion

Sources for Chromosome 12p Deletion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....